Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 January, 2018 00:55 IST
Zydus Cadila gets USFDAs final nod for Phentermine HCl tablets
Source: IRIS | 30 Jun, 2017, 10.10AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Phentermine Hydrochloride Orally Disintegrating Tablets in strengths of 15 mg, 30 mg, and 37.5 mg.

The drug is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Shares of the company gained Rs 3.55, or 0.68%, to trade at Rs 525.45. The total volume of shares traded was 16,403 at the BSE (10.03 a.m., Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Reliance Q3 profit up 25.5%; GRM at USD 11.6/bbl - 19-Jan-2018 18:34
HDFC Bank Q3 net grows 20% to Rs 41.51 bn - 19-Jan-2018 18:07
Wipro Q3 earnings fall 12% q-o-q to Rs 19.3 bn - 19-Jan-2018 17:56
Lupin launches generic Vibra-Tabs tablet in US - 19-Jan-2018 15:56
HCL Tech Q3 profit jumps 6% to Rs 21.94 bn - 19-Jan-2018 11:45
Suven Life Sciences secures 2 overseas product patents - 18-Jan-2018 15:26
Yes Bank Q3 profit rises 22% to Rs 10.76 bn - 18-Jan-2018 15:24
Sanghvi Forging & Engg bags new orders worth Rs 110 mn - 18-Jan-2018 10:17
Tata Consultancy Services expands partnership with Shure Inc - 18-Jan-2018 10:13
L&T Technology Services bags USD 50 mn avionics contract - 18-Jan-2018 10:07
Dilip Buildcon wins NHAI road project worth Rs 7.30 bn - 18-Jan-2018 10:01
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer